215 | DISCONTINUATION OF BTK INHIBITOR MONOTHERAPY IN CLL PATIENTS WITHOUT DISEASE PROGRESSION: A REAL‐WORLD STUDY FROM THE SPANISH CLL GROUP (GELLC)
A. C. Oliveira, C. Arévalo, Eva González‐Barca, M. Alcoceba et autres
es (code pays fourni par la source)